Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard | 100.211.853 |
Chemical and physical data | |
Formula | C33H45N3O8S |
Molar mass | 643.80 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Satavaptan ( INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist [1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. [2] Development was discontinued in 2009. [3]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard | 100.211.853 |
Chemical and physical data | |
Formula | C33H45N3O8S |
Molar mass | 643.80 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Satavaptan ( INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist [1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. [2] Development was discontinued in 2009. [3]